Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
18hon MSN
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback